A156
HOSPITAL FRAILTY RISK SCORE IS AN INDEPENDENT PREDICTOR OF OUTCOMES IN CUTANEOUS SQUAMOUS CELL CARCINOMAS OF HEAD AND NECK REGION.
Skin Cancer
Rema A Kandula, MD; Sandeep Kandregula, MD; Bharat Guthikonda, MD; John Pang, MD; Ameya Asarkar, MD; Cherie-Ann O Nathan, MD
LSU Health sciences Shreveport
A157
THE ARGUMENT FOR ADJUVANT THERAPY FOR STAGE II HEAD AND NECK MELANOMA- COULD A NOMOGRAM ASSIST DECISION MAKING?
Helena Levyn, MD; Schlomo Schneebaum, MD
Tel Aviv Sourasky Medical Center
A158
CUTANEOUS SQUAMOUS CELL CARCINOMA IN IMMUNOCOMPROMISED PATIENTS- A COMPARISON BETWEEN DIFFERENT IMMUNOMODULATING CONDITIONS
Ofir Zavdy, MD, MPH; Tara Coreanu, MD; Dvir Bar On, MD; Amit Ritter, MD; Gideon Bachar, MD; Thomas Shpitzer, MD; Noga Kurman, MD; Muhammad Mansour, MD; Dean Ad-El, MD; Uri Rozovski, MD; Gilad Itzhaki, MD; Shani Sherman-Bergman, MD; Limor Azulay-Gitter, MD; Aviram Mizrachi, MD
Rabin Medical Center
A159
A VACCINE FOR SKIN CANCER?: PREVIOUS HPV-POSITIVE CANCER AND HPV VACCINATION ASSOCIATION WITH CUTANEOUS SQUAMOUS CELL CARCINOMA
Susan Kurian, MD; Gauri Shishodia, PhD; Ashley Flowers, MD; Brent Chang, MD, FACS; Cherie-Ann O Nathan, MD, FACS
Ochsner LSU Health Shreveport
AHNS Annual Meeting
Held during the Combined Otolaryngology
Spring Meetings (COSM)
April 27-28, 2022
Hyatt Regency Dallas
Dallas, TX